Advances in treatment of double-hit lymphoma

VernacularTitle:双重打击淋巴瘤治疗研究进展
Author: Fangwen ZHANG ¹ ; Ling LI ; Xiaoyan FENG ; Zhaoming LI ; Mingzhi ZHANG
Author Information

1. 450052,郑州大学第一附属医院肿瘤科河南省淋巴瘤诊疗中心
Keywords: Lymphoma,B-cell; Double-hit lymphoma; Diagnosis; Treatment; Prognosis
From: Journal of Leukemia & Lymphoma 2018;27(11):700-704
CountryChina
Language:Chinese
Abstract: High grade B-cell lymphoma was defined as an independent disease in the 2016 new version of the World Health Organization lymphoma classification, including double-hit high grade B-cell lymphoma with myc and bcl-2 or bcl-6 gene rearrangements and high grade B-cell lymphoma, not otherwise specified without myc and bcl-2 or bcl-6 gene rearrangements, both of them are invasive in clinical features. In recent years, there have many studies on it, double-hit lymphoma (DHL) has relatively unique clinical features and poor prognosis. Although high-intensity chemotherapy can prolong the survival of patients, current treatment options have poor efficacy, and specific targeted drug therapies are still required. Single-agent or combination therapy of signal pathway inhibitors can improve the poor prognosis of patients. Immunotherapy is expected to become the direction of future research. This article reviews the definition, diagnosis, prognosis, and latest treatment progress of DHL.